Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6-amino-2-[(2-morpholin-4-ylethyl)amino]-3,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
This compound is a synthetic small molecule with the chemical formula C15H19N7O2 and a molecular weight of approximately 329.36 g/mol. It features a fused imidazo and quinazoline ring system with an amino group at position 6 and a morpholine-containing side chain at position 2. The compound is classified as an organoheterocyclic molecule within the diazanaphthalene/benzodiazine/quinazoline family. It has been cataloged in chemical databases such as PubChem (CID: 135566918), DrugBank (DB07564), ChemSpider (ID: 25057771), and RCSB PDB ligand database under the code CKR. There are no known approved medical indications or clinical trials for this compound; it is considered experimental and primarily used in research contexts to study structure–activity relationships or as a fragment for drug design targeting nucleic acid-modifying enzymes or related proteins[1][2][3][9].
- Other names
- 6-Amino-2-{[2-(morpholin-4-yl)ethyl]amino}-3H,7H,8H-imidazo[4,5-g]quinazolin-8-one6-amino-2-{[2-(morpholin-4-yl)ethyl]amino}-3H,7H-imidazo[4,5-g]quinazolin-8-onelin-benzoguanine scaffold, 9
Beyond the preview
Go deeper on 6-amino-2-[(2-morpholin-4-ylethyl)amino]-3,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 6-amino-2-[(2-morpholin-4-ylethyl)amino]-3,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one.